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A b s t r a c t
Introduction: Hypertension is one of the main risk factors of cardiovas-
cular diseases. The first aim of the study was to evaluate the prevalence, 
awareness and treatment of hypertension as well as treatment effective-
ness (blood pressure < 140/90  mm Hg) in a  representative sample of the 
Polish population over the age of 19, examined in the WOBASZ II program. 
The second aim was to assess the changes in these parameters between 
2003–2005 (WOBASZ study) and 2013–2014 in adults aged 20–74.
Material and methods: Sampling was performed in three stages, stratified 
according to voivodeship (province), type of commune, and gender. Finally, 
the study included 6163 persons (3406 women and 2757 men) examined 
in the years 2013–2014 (aged ≥ 19 years). For comparison the data from 
14 755 persons (7783 women and 6452 men aged 20–74 years) examined 
in the years 2003–2005 were used.
Results: In the years 2013–2014, the age-standardized prevalence of hy-
pertension, awareness, treatment and control was 42.7%, 59.3%, 46.1%, 
and 23% respectively. In the last decade an increase in the prevalence of 
hypertension (relative  ratio (RR) 1.12; 95% confidence interval (CI): 1.07–
1.18), treatment (RR = 1.26; 95% CI: 1.17–1.36) and control (RR = 2.16; 
95% CI: 1.91-2.45) was found. In contrast, the awareness decreased nonsig-
nificantly (RR = 0.98; 95% CI: 0.92–1.05).
Conclusions: The prevalence of hypertension in Poland is high, and in-
creased by about 12% in 10 years. Although the number of treated patients 
and blood pressure control improved nearly twofold over the last decade, 
this is still below expectations. Efforts to improve the diagnosis and effec-
tive treatment of hypertension in Poland should still be intensified.
Key words: health examination surveys, clinical epidemiology, prevalence 
of hypertension, awareness of hypertension, treatment of hypertension, 
control of hypertension.
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Introduction
All over the world, hypertension is the main 
modifiable risk factor for all cardiovascular disease, 
including coronary artery disease, stroke, heart fail-
ure, peripheral artery disease, and renal failure [1]. 
According to the WHO, an elevated blood pressure 
(BP) is the leading risk factor of death in the world 
[2]. According to American epidemiological studies, 
hypertension is responsible for up to 40.6% of car-
diovascular mortality, while smoking is responsible 
for 13.2%, poor diet for 11.9%, insufficient physical 
activity for 8.8%, and elevated plasma glucose for 
8.8% [3]. It is estimated that mortality due to car-
diovascular diseases and stroke caused by elevat-
ed pressure is doubled with an increase in systolic 
BP (SBP) of 20 mm Hg and diastolic pressure of 
10 mm Hg. It was demonstrated in meta-analyses 
of Hebert and MacMahon including randomized 
clinical trials concerning pharmacological treat-
ment of patients with mild to moderate hyperten-
sion that even a slight decrease in mean diastolic 
BP (DBP) of 3–6 mm Hg resulted in a significant 
reduction in stroke incidence by 40–42% and 
cardiovascular events by 16–25% [4]. The study 
conducted by Farley demonstrated that about 
a  10% improvement in diagnosis and treatment 
of hypertension prevented 14,000 deaths a  year 
in a  population of adult Americans aged 25–75. 
For comparison, a 10% improvement in diagnosis 
and treatment of elevated low-density lipoprotein 
(LDL) cholesterol level, or an implementation of 
aspirin treatment in patients with high risk of car-
diovascular mortality prevented 8,000 deaths [5]. 
In Poland, the share of cardiovascular diseases 
(CVDs) as a  cause of mortality has been gradu-
ally decreasing since 1991. In 1991, CVDs were 
the cause of 47.7% of deaths (42.8% in men and 
53.3% in women) [6]. In 2014, 169  735 people 
died due to CVDs (441.1/100 000). They were re-
sponsible for 45.8% of all deaths of Poles (40.9% 
in men and 51.1% in women) [7]. The age-stan-
dardized factor of mortality due to CVDs de-
creased by 27% in men and 30% in women in the 
years 1991–2013 [6]. A meta-analysis conducted 
by Kearney, which included studies on adults from 
30 countries, demonstrated that the prevalence of 
hypertension in adults in the world in 2000 was 
26.4% (972 million people), and it is estimated to 
grow by 2025 to 29.2% (1650 million patients) [8]. 
Based on the results of the NATPOL 2011 study, an 
increase in the number of hypertensive patients 
aged 18–79 to about 14 million is predicted in Po-
land by the year 2035 (after taking account of the 
Central Statistical Office (CSO) demographic fore-
cast and directions of changes in the prevalence 
of risk factors in the period 2002 to 2011 (the 
aim of the Polish nationwide NATPOL 2011 study 
was assessment of prevalence and control of se-
lected risk factors of CVD including hypertension)) 
[6]. Knowledge of the prevalence, detection and 
efficiency of hypertension treatment at the pop-
ulation level is extremely important for planning 
the strategy to reduce cardiovascular diseases in-
cidence and health protection expenditures. The 
largest Polish epidemiological study evaluating 
the health status of Poles is the WOBASZ study 
(Multi-center National Population Health Exam-
ination Survey), whose first edition was conduct-
ed in 2003–2005, and the second in 2013–2014.
The first aim of the study was to evaluate the 
prevalence, awareness and treatment of hyper-
tension as well as treatment effectiveness (BP 
< 140/90 mm Hg) in a  representative sample of 
the Polish population over the age of 19 years, ex-
amined in the WOBASZ II program. 
The second aim was to assess changes in these 
parameters in 2003–2005 and 2013–2014 in 
adults aged 20–74.
Material and methods
The methodology (study protocol, training 
materials, a  set of questionnaires and instruc-
tions concerning every element of the study) 
was prepared using the combined experience of 
the POL-MONICA project (Polish part of the WHO 
MONICA Project), first edition of WOBASZ and 
guidelines of the European Health Examination 
Survey (EHES) [9, 10]. The WOBASZ II program 
was accepted by the Field Bioethics Committee 
of the Institute of Cardiology in Warsaw. Finally, 
the WOBASZ study included 14 755 people (7783 
women and 6972 men) and the WOBASZ II study 
included only 6163 patients (3406 women and 
2757 men; initially it was intended to examine 
15 120 people), due to the participation rate that 
was 76.9% and 45.5% respectively. WOBASZ II 
included the same municipalities as the first edi-
tion, but the randomized sample of individual par-
ticipants was independent. Sampling had three 
stages, stratified according to voivodeships (prov-
inces), type of communes, and gender. A detailed 
description of the study methodology is provided 
in a separate paper [6, 10, 11].
Blood pressure measurements were performed 
according to the recommendations of PTNT 2015 
(Polish Society of Hypertension) [12] consistent 
with the recommendations of the ESC/ESH 2013 
(European Society of Cardiology/European Society 
of Hypertension) [13]. 
Pressure measurements took place during 
a single visit, and were performed using the au-
tomatic device AND UA-631 (in the WOBASZ 
study the automatic device OMRON M-51 was 
used [10]), approved by the AAMI (Association for 
the Advancement of Medical Instrumentation). 
Arm circumference was measured before pres-
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sure measurement, in order to select an appro-
priate width of the cuff. The measurement was 
performed three times at two-minute intervals 
on the right upper arm in a sitting position after 
5 min of rest (in the WOBASZ study the BP mea-
surement protocol was identical [10]). An average 
value from the second and third measurement 
were accepted for an evaluation of BP value in the 
examined patient. In cases where three BP mea-
surements were not performed, a single measure-
ment or an average of two measurements was 
taken into account. 
The following definitions were accepted ac-
cording to the recommendations of the World Hy-
pertension League Expert Committee [14]:
•  Hypertension is defined as presence of SBP 
≥ 140 mm Hg or DBP ≥ 90 mm Hg or use of 
BP-lowering medication (regular for last 2 weeks).
•  Awareness of hypertension is defined as the 
proportion of patients with hypertension who 
report either having been diagnosed with hyper-
tension by a health professional or who report 
taking medication for high BP to hypertensive 
patients (affirmative response to the questions: 
“Have you ever been told by a doctor that you 
had hypertension, also called high blood pres-
sure?” and “Have you ever taken medicine pre-
scribed because of high blood pressure?”
 Treatment of hypertension is defined as the pro-
portion of patients with hypertension who report 
taking medication for high BP to hypertensive 
patients (affirmative response to the questions: 
“Have you taken this medicines regularly during 
the last 2 weeks?”).
•  Controlled hypertension is defined as the pro-
portion of patients with hypertension who both 
report taking medication for high BP and have 
SBP < 140 mm Hg and DBP < 90 mm Hg to hy-
pertensive patients.
We are aware that ESH BP categories can be 
applied only to an untreated population. The de-
scribed stages of hypertension concerned the 
whole population, including those treated. How-
ever, the same methodology of presentation of 
results was adopted in a previous publication on 
the WOBASZ study. Thanks to that we obtained 
results we could compare and could evaluate 
changes in the prevalence of raised blood pres-
sure in the Polish population.
The patients were qualified for the group with 
optimal pressure, according to the recommenda-
tions of PTNT 2015 and ESC/ESH 2013 [12, 13], 
when SBP < 120 mm Hg and DBP < 80 mm Hg, 
with normal BP when SBP was 120–129 mm Hg 
and/or DBP 80–84 mm Hg, and high normal pres-
sure when SBP was 130–139 mm Hg and/or DBP 
85–89 mm Hg. First degree hypertension was 
diagnosed when SBP was 140–159 mm Hg and/
or 90–99 mm Hg, second degree when SBP was 
160–179 mm Hg and/or DBP 100–109 mm Hg, 
third degree when SBP was ≥ 180 mm Hg and/or 
DBP ≥ 110 mm Hg.
Statistical analysis 
All data obtained during the study were record-
ed in individual questionnaires. Then they were 
transferred to the database created in Excel Office 
2013. Parameters such as pressure values were 
described using the arithmetic mean and stan-
dard deviation. Crude prevalence of hypertension, 
awareness, frequency of treatment, and BP control 
(as defined above) were described as percentages, 
with the 95% confidence interval (95% CI), for the 
following age ranges: 19–49, 50–59, 60–69, 70–79 
and above 80. Age-standardized prevalence rates 
were calculated with the direct method using 
weights assessed for the population of Poland at 
the end of 2013 [11]. In assessment of compati-
bility of the distribution of the WOBASZ II popula-
tion and CSO population (population of Poland by 
sex and age as of December 31, 2013, according 
to CSO data), the Wilcoxon signed rank and sign 
test were compared (p = 0.766 and p = 0.902 re-
spectively). Obtained results are a proof of good 
matching of the WOBASZ group to the standard 
CSO population.
The compatibility with a  normal distribution 
was examined using the Lilliefors test. Paramet-
ric tests were used for parameters consistent 
with a  normal distribution; otherwise non-para-
metric tests were used. The t-test for unmatched 
pairs or Mann-Whitney test was used to compare 
mean values between the tests and between the 
groups of men and women. Frequencies of ana-
lyzed features were compared using the c2 test. 
To compare data from the WOBASZ II study with 
those from the first edition WOBASZ study, which 
included adults aged 20 to 74 years, we used re-
stricted data from the WOBASZ II study for peo-
ple aged 20 to 74 years. The rate ratio (RR) with 
95% CI was calculated by dividing the standard-
ized frequency of the above-listed parameter in 
order to evaluate the changes in the prevalence of 
optimal, normal, high-normal pressure, grade I, II 
and III hypertension, prevalence of hypertension, 
awareness, treatment and control of hypertension 
between WOBASZ and WOBASZ II studies. An RR 
value lower than 1.0 indicated a decreased, and 
above 1.0 an increased prevalence. 
Spearman correlation was used to assess the 
relationship between prevalence of hypertension 
and participation rate in 16 voivodships. Statisti-
cal hypotheses were verified at a significance level 
of p < 0.05. The calculations were performed using 
the statistical package Statistica PL (data analysis 
software system) StatSoft, Inc. (2016) version 12.
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Results
Three pressure measurements in accordance 
with the established protocol were performed in 
98.35% of the patients. In 99.72%, the pressure 
measurements were conducted in a  sitting po-
sition. In 33.3% of cases the arm circumference 
was equal to or greater than 32 cm, and pressure 
measurement was made using the cuff bigger 
(size L: 33–45 cm) than the standard one (size M: 
22–32 cm), and in 0.8% of the patients the arm 
circumference was below 22 cm. Blood pressure 
distribution demonstrated an increase in SBP 
with an age up to about 75 years in both men and 
women. Then a further increase in SBP is observed 
in women over 75 years of age, and its decrease 
in men over 75 years of age. Distribution of DBP 
was slightly different – its growth, plateau and de-
crease with age were noted in men, while the sit-
uation in women was similar, with one difference 
– an increase in DBP was observed from about 
75 years of age. Mean SBP values for women were 
significantly lower than for men in all analyzed 
5-year age ranges up to 65 years of age. Similar-
ly, average values of DBP for women were signifi-
cantly lower than for men in all analyzed 5-year 
age ranges up to 60 years of age (Figure 1). 
Optimal pressure was observed significant-
ly more frequently in women than in men in the 
whole examined population (34.2% vs. 17.6%; 
p < 0.00001). High normal pressure and first de-
gree hypertension were observed significantly 
more often in men than in women in the whole 
 21–25 26-30 31–35 36–40 41–45 46–50 51–55 56–60 61–65 66–70 71–75 76–80 > 80
Age [years]
                                          N =  439 487 565 576 528 534 674 653 623 397 273 226 188
 Men          Women
Vertical bars represent 95% confidence intervals
Figure 1. Mean systolic and diastolic blood pressure by age group in WOBASZ II study
M
ea
n 
sy
st
ol
ic
 b
lo
od
 p
re
ss
ur
e 
[m
m
 H
g]
M
ea
n 
di
as
to
lic
 b
lo
od
 p
re
ss
ur
e 
[m
m
 H
g]
155
150
145
140
135
130
125
120
115
88
86
84
82
80
78
76
74
72
70
68
Prevalence, awareness, treatment and control of hypertension in the adult Polish population – 
Multi-center National Population Health Examination Surveys – WOBASZ studies
Arch Med Sci 5, August / 2018 955
examined group (respectively 26.0% vs. 17.5%; 
p = 0.0001 and 22.3% vs. 15.9%; p < 0.0001). No 
significant differences were demonstrated in the 
prevalence of normal, second and third degree hy-
pertension between men and women. Percentage 
distributions of optimal, normal and high normal 
SBP and DBP, as well as first, second and third de-
gree hypertension, are presented in Table I.
After age standardization, the prevalence of 
hypertension was 42.7% in the entire population 
of the WOBASZ study, and was highest in the 
age group 70–79. Having in mind the entire an-
alyzed age range, hypertension was significantly 
more often noted in men than in women (46.2% 
vs. 40.4%; p < 0.00001). The greatest awareness 
of the disease was observed in patients after 
50 years of age. This was significantly higher in 
women than in men in all age groups (63.2% vs. 
55.3%; p = 0.00005). Pharmacological therapy was 
the most commonly implemented in older age – 
after 60 years of age. In the entire population of 
the WOBASZ II study, women were treated sig-
nificantly more often than men (52.1% vs. 40.2%; 
p < 0.00001). Good BP control was obtained in 
23% in the whole examined group, and in 51.9% 
with respect to treated patients. Pressure normal-
ization was achieved in a  higher percentage in 
women than in men (27.3% vs. 19.0%; p = 0.0091). 
The worst pressure control was observed in men 
and women aged 19–49. The prevalence, aware-
ness, and percentage of treated patients, including 
those treated effectively, are presented in Table II. 
Among people included in WOBASZ and 
WOBASZ II studies, mean SBP decreased (mean 
± standard deviation) from 137.6 ±18.9  mm Hg 
to 132.7 ±17.7 mm Hg in men (p < 0.00001), and 
from 129.7 ±22.1 mm Hg to 125.0 ±18.8 mm Hg in 
women (p < 0.00001), while mean DBP decreased 
from 83.9 ±11.8 mm Hg to 81.3 ±10.6 mm Hg and 
81.3 ±12.0 mm Hg to 78.7 ±10.6 mm Hg, respec-
tively (p < 0.00001).
Changes in the prevalence of BP classes, i.e. op-
timal, normal, high normal BP, and grades I–III hy-
pertension, in a subsample age restricted to 20–
74 years are presented as rate ratios in Figure 2.
During the last decade, both in men and in 
women, there was a  significantly increased per-
centage of persons with optimal and normal BP 
and first degree hypertension and a  decreased 
percentage of persons with high normal BP and 
second and third degree hypertension. 
Changes in the prevalence of hypertension, 
awareness, treatment and control of BP in a sub-
sample age restricted to 20–74 years are present-
ed as rate ratios in Figure 3.
After standardization for age and sex, the prev-
alence of hypertension among people included in 
WOBASZ and WOBASZ II studies increased from 
34.7% to 39% (RR = 1.12; 95% CI: 1.07–1.8); in 
men from 38.1% to 44.3% (RR 1.16; 95%CI: 1.09–
1.25), in women from 32.3% to 35% (RR = 1.08; 
95% CI: 1.01–1.16). Hypertension awareness de-
creased from 55% to 54.2% (RR = 0.98; 95% CI: 
0.92–1.05); in men it increased from 51.6% to 
52.3% (RR = 1.01; 95% CI: 0.92–1.11) and in wom-
en decreased from 59.2% to 54.7% (RR = 0.92; 
95% CI: 0.84–1.01). Comparing WOBASZ studies, 
an improvement was observed – the number of 
treated patients increased from 32% to 40.5% 
(RR = 1.26; 95% CI: 1.17–1.36); in men it in-
creased from 26.9% to 37.5% (RR = 1.39; 95% CI: 
1.24–1.57) and in women from 38.2% to 42.9% 
(RR = 1.24; 95% CI: 1.11–1.40). Also BP control 
improved twofold – it increased from 9.6% to 
20.7% (RR = 2.16; 95% CI: 1.91–2.45); in men it 
increased from 7.6% to 17.5% (RR = 2.34; 95% CI: 
1.93–2.82) and in women from 12.0% to 23.8% 
(RR = 1.99; 95% CI: 1.69–2.35). 
Discussion 
The average values of SBP and DBP (analyzed 
in the whole population – in patients with and 
without diagnosed hypertension) over the last 
10 years in Poland decreased during the decade be-
tween 2003/2005 (WOBASZ) [15] and 2013/2014 
(WOBASZ II). We relate this to an increase in the 
number of patients with implemented effective 
antihypertensive therapy, and an increase in the 
number of patients with improved BP control. Less 
likely, the shift to a more favorable distribution of 
BP could be related to life style modification. Oth-
er findings of the WOBASZ II study suggest that 
both diet and physical activity changed to less 
favorable patterns, which was reflected in unfa-
vorable changes in blood lipids and prevalence of 
obesity [16–19]. These data are part of a  global 
trend in which a decrease in both SBP and DBP 
was observed in recent years. Between 1980 and 
2008, age-standardized average SBP was reduced 
from 130.5 mm Hg to 128.1 mm Hg in men, which 
gives a decrease of 0.8 mm Hg per decade, and 
from 127.2  mm Hg to 124.4 mm Hg in women, 
which means a  decrease of about 1.0 mm Hg 
per decade [20].
Only 27.1% of the patients aged 19–99 years 
had optimal BP. This percentage was significantly 
higher for women than for men (34.2% vs. 17.6%; 
p < 0.00001). For comparison, in the English popu-
lation aged 20–79 years the corresponding figures 
were 34.2%, for the US population 50.3%, and for 
the Canadian population 66.1% [21].
In the present study, repeated BP measurement 
(three times) took place in one visit. According to 
current recommendations of ESH/ESC 2013 [13] 
and PTNT 2015 [12], the diagnosis of hypertension 
is based on at least two pressure measurements 
during two separate visits. The implementation of 
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Figure 2. Changes in prevalence of BP classes, i.e. 
optimal, normal, high normal BP, grade I–III hyper-
tension in a  subsample age restricted to 20–74 
years in WOBASZ studies
All – all population, M – men, W – women.
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Figure 3. Changes in the prevalence of hyper-
tension, awareness, treatment and control of BP 
in a  subsample age restricted to 20–74 years in 
WOBASZ studies
All – all population, M – men, W – women.
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these recommendations to epidemiological stud-
ies is difficult. Taking the measurements at only 
one visit leads to higher average values of BP and 
to an overestimation of hypertension prevalence 
in the examined population, and an underesti-
mation of awareness of this disease and effec-
tiveness of treatment. The differences in meth-
odology concerning hypertension diagnosis cause 
a problem in interpretation and comparison of the 
epidemiological situation in different countries. 
A  meta-analysis of Kearney et al. [8], evaluating 
hypertension prevalence in 40 countries, includ-
ed studies with different numbers of visits and 
BP measurements – both based on one visit (e.g. 
Spanish, English, German, Greek, Italian, studies) 
and on two visits (American, Canadian studies). It 
was the basis of hypertension prevalence estima-
tion in the world in 2000 at a level of about 26.4% 
(95% CI: 26.0–26.8%). The study conducted in 
2001–2003 by Figueiredo on the Portuguese pop-
ulation aged above 45 demonstrated the preva-
lence of hypertension at the level of 63.4%, 60.2%, 
56.3% (p < 0.001), for the measurements based on 
the first visit, the second visit, and the average of 
the first and second visit, respectively. According to 
the authors of this study, pressure measurement 
at only one visit resulted in an overestimation of 
hypertension prevalence of 12.6% [22]. 
Prevalence of hypertension in the HYDY study 
conducted in 2007 on the Yemeni population aged 
15–69, estimated based on measurements from 
a  single visit, was 17.3% and was 35% higher 
than that calculated on the basis of the measure-
ments from two different visits, which was 11.3% 
[23]. In the Polish NATPOL PLUS study from 2002, 
hypertension diagnosis was based on the mea-
surements performed in the homes of the respon-
dents during three separate visits. The prevalence 
of hypertension according to the number of visits 
was 36.4%, 31.3% and 29.4% for 1, 2 and 3 visits, 
respectively [6, 24].
Taking into account the results of the Portuguese 
study, the closest to Polish socio-economic and ep-
idemiological conditions, as well as the results of 
the NATPOL PLUS study, we recognize that our re-
sults may be higher by about 15%. Attention should 
be paid to the high prevalence of hypertension in 
the WOBASZ II population – up 42.7%, significant-
ly different from that observed in other developed 
countries (Table III). Similar results were observed in 
Bosnia and Herzegovina as well as in Greece. 
Epidemiological data from around the world 
are divergent – depending on the region of resi-
dence, hypertension occurs with varying frequen-
cy in men and women (Table III). 
According to the WHO report of 2015 [25], 
higher prevalence of hypertension in men than in 
women was found in countries with a socio-eco-
nomic profile (i.e. Central and Eastern Europe 
countries) similar to the Polish population, e.g.: 
35.2% and 24.3% in Lithuania, 34.6% and 23.1% 
in Hungary, 33.2% and 21% in the Czech Repub-
lic, for men and women, respectively. The situa-
tion is similar in Western Europe; in 2010, in the 
population aged over 20, hypertension occurred 
more frequently in women than in men: 23.3% vs. 
20.7% in the UK, 20.0% vs. 14.8% in Spain, 22.3% 
vs. 17.6% in Italy, 25.1% vs. 22.9% in Germany 
[26]. Women suffer from hypertension more fre-
quently than men in some African countries, e.g. 
in 32.0% and 27.7% in Lesotho for women and 
men, respectively [25]. In 2015, global age-stan-
dardized prevalence of raised blood pressure was 
24.1 in men and 20.1% in women [27]. 
The awareness, percentage of treated patients 
and blood pressure control have improved over 
the last decade, and in the WOBASZ II study in 
the whole population aged 19–99 years they were 
59.3%, 46.1% and 23%, respectively. As a  result, 
we approached the best countries in this range. 
The awareness of hypertension in the NHANES 
study in 2009–2012 in patients above 20 years 
Prevalence, awareness, treatment and control of hypertension in the adult Polish population – 
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Table III. Hypertension prevalence in selected countries
Study Country Year Population
[years]
No. of  
measurements
No. of 
visits
Prevalence of hypertension (%)
Overall Men Women
NHANES USA 2007–2010 20–79 3 (mean 2 and 3) 1 29.1 29.4 28.8
The Canadian 
Health 
Measures 
Survey
Canada 2007–2009 20–79 6 (mean 2–6) 2 19.5 19.7 19.3
Health Survey 
for England
England 2011 ≥ 16 3 (mean 2 and 3) 1 30 32 28
PatenT 2 Turkey 2012 > 18 3 1 30.3 28.4 32.3
DEGS1 Germany 2008–2011 18–79 3 (mean 2 and 3) 1 32 33.4 30
Pilav et al. Bosnia and 
Herzegovina
2012 > 18 3 (mean 2 and 3) 1 42 43.9 37.5
EPIC Greece 2004 20–86 2 1 44.4 45.2 43.8
of age was noted in about 82.7% of patients, and 
76.5% of them were treated, including 54.1% who 
achieved good BP control [9]. The absolute leader in 
the care related to hypertension is Canada, where 
the greatest awareness of hypertension was report-
ed (83.4%), the highest percentage of patients had 
antihypertensive treatment implemented (79.9%), 
and good BP control was achieved in the largest 
number of patients – up to 65.8% [21]. Such good 
results were not achieved in countries which, like 
Poland, reported a high prevalence of hypertension. 
In 2012, awareness of the disease in the population 
of Bosnia and Herzegovina was reported by 48.6% 
of respondents, 40.3% of men and 57.2% women. 
In this study, 35.5% of men and 54.2% of women 
were treated, but good pressure control was ob-
served in only 9% of men and 22.2% of women [28]. 
It is not possible to compare easily Polish epi-
demiological studies, i.e. the NATPOL PLUS study 
of 2002 [6, 24], the WOBASZ study of 2005 [6, 
15, 24], NATPOL 2011 [6, 24] and the WOBASZ II 
study. However, all these studies were carried out 
on a  representative group of Polish citizens, but 
they included different age ranges of the exam-
ined population, 18–94, 20–74, 19–79 and 19–99, 
respectively. Therefore, in presenting the results of 
the WOBASZ II study, it was necessary to make 
additional calculations for the age 20–74, so that 
it was possible to compare both WOBASZ stud-
ies. Another difference in NATPOL and WOBASZ 
studies was the number of visits – the NATPOL 
PLUS study involved three visits (the results were 
described for 2 visits), NATPOL 2011 involved two 
visits, and the WOBASZ study involved one visit. 
The prevalence of hypertension has increased 
in Poland since 2002. In the NATPOL study, it in-
creased from 30% to 32% between 2002 and 
2011 [24]. This increase was higher in WOBASZ 
studies – from 34.7% to 39.0% in the whole popu-
lation. An increase in the number of patients with 
hypertension between 2010 and 2025 is predict-
ed in many Western European countries, and is 
expected to reach 9% in Germany, 17% in France 
and Italy, 18% in Britain and 22% in Spain [26].
The increase in hypertension diagnosis is ob-
served both in NATPOL and WOBASZ studies. 
Awareness of the disease in the NATPOL study in-
creased within a decade from 66% to 72% [24]. 
A  different trend was observed in WOBASZ and 
WOBASZ II studies – awareness of the disease 
showed an insignificant decrease from 55.2% to 
54.2%. The care of patients with hypertension 
in Poland shows continuous improvement. The 
number of patients with implemented treatment 
is increasing, and its control is improving. The ef-
fectiveness of hypertension treatment in NATPOL 
PLUS and NATPOL 2011 studies measured by the 
percentage of patients with SBP < 140 mm Hg and 
DBP < 90 mm Hg among all patients with hyper-
tension increased over 10 years from 12% to 26% 
[24]. This could be the effect of growing atten-
tion to hypertension over the last decades both 
among professionals and the general public. The 
important signs were introduction of hypertensi-
ology specialization in 2005 (now, there are 304 
professionals in this field in Poland) [29] and very 
intensive training activities of the Polish Society 
of Hypertension, which in 2008 and 2011 issued 
guidelines for the diagnosis and treatment of hy-
pertension, and organized a number of seminars 
and workshops addressed to general practitioners. 
An important role was played by national proj-
ects that were introduced in Poland in 2003 as 
part of the National Program for Prevention and 
Treatment of Cardiovascular Diseases POLKARD 
(the Polish 400 Cities Project: screening and ed-
ucational program for citizens of 400 small cities, 
Polkard-Media: education of general population 
using TV and radio, SMS: educational multimedia 
program for children in schools) [24]. 
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Also public current expenditures on health 
care have increased in recent years. In 2004, they 
amounted to around 37 billion PLN (about $9.5 
billion, $1 = 4 PLN), which accounted for 4.02% 
of GDP (gross domestic product), and in 2012 was 
70.7 billion PLN (about $17.5 billion), which repre-
sented 4.43% of GDP [30].
One strength of the WOBASZ II study is the 
large group of examined people, n = 6170. Af-
ter the WOBASZ study of 2005 (n = 14  769), it 
is the largest Polish epidemiological study con-
cerning hypertension. For example, another study 
– the last edition of NATPOL of 2011 – involved 
only 2404 people. The main strength of the study 
would be that the examined group was a strati-
fied random sample, which was representative for 
the Polish population aged over 19 years.
On the other hand, the study had a  low par-
ticipation rate, so selection bias towards overrep-
resentation of healthy people could be expected. 
Further, participation in WOBASZ II was lower than 
10 years ago (45.5% vs. 70.5%; frequency among 
women was 10% higher than in men; it was also 
lower than in the NATPOL 2011 study, where it was 
66.5%) [24]. It is similar to the rate observed in the 
12 European countries participating in the EHES 
study (European Health Examination Survey Pilot 
Project) in 2009–2012, which ranged from 16% to 
57% in men, and from 31% to 74% in women [31]. 
However, there was no significant correlation be-
tween the response rate in 16 voivodships and the 
prevalence of hypertension (r = 0.17; p = 0.516), 
awareness (r = 0.31; p = 0.2351), treatment (r = 
0.15; p = 0.569), control (r = 0.27; p = 0.3108, op-
timal (r = 0.2; p = 0.4668), normal (r = 0.33; p = 
0.207), and high normal BP (r = –0.12, p = 0.6485).
Another weakness of this study was that BP 
measurements were made only at one visit. This 
could have resulted in an overestimation of hyper-
tension prevalence in Poland and led to underesti-
mation of its control.
In conclusion, the prevalence of hyperten-
sion in Poland is high, and increased by about 
12% within the decade between 2003/2005 and 
2013/2014. Although the proportion of treated 
patients and in particular the proportion of pa-
tients reaching the treatment target increased 
over twofold, it is still lower than the average in 
Western Europe, USA or Canada. Efforts to im-
prove the diagnosis and effective treatment of 
hypertension in Poland should be intensified, 
both in primary care and specialized treatment, 
especially in young people. 
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